Company Overview and News

 
Artamon is the new engineering hub

2018-03-23 theage.com.au
The engineering sector has a new hub on the leafy lower North Shore as they slowly replace the more traditional industrial users.
Upvote Downvote

 
Artamon is the new engineering hub

2018-03-23 smh.com.au
The engineering sector has a new hub on the leafy lower North Shore as they slowly replace the more traditional industrial users.
Upvote Downvote

 
BHP, Rio, CBA, Woodside, NAB face dividend payout pressure: Morgan Stanley

2018-03-19 theage.com.au
Labor's proposed changes to dividend imputation will place more pressure on companies with excess franking credits to pay out more to shareholders.
Upvote Downvote

 
BHP, Rio, CBA, Woodside, NAB face dividend payout pressure: Morgan Stanley

2018-03-19 smh.com.au
Labor's proposed changes to dividend imputation will place more pressure on companies with excess franking credits to pay out more to shareholders.
Upvote Downvote

 
S&P/ASX 200 closes down 0.7% after 5-day winning run

2018-02-28 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has closed today just above its low for the day of 6,012.6 ending the index's winning streak.
Upvote Downvote

 
S&P/ASX 200 down 0.4%, AUD lower as China PMI data misses

2018-02-28 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has failed to rally from its 11.00am low of 6,026 and is hovering around the 6,030 level.
Upvote Downvote

 
S&P/ASX 200 trying to bounce but still down 0.3% around midday

2018-02-28 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has bounced from its 11.00am low of 6,026 to only be down 20 points around midday.
Upvote Downvote

 
S&P/ASX 200 opens lower as expected, down 0.3% in early trade

2018-02-27 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has followed in the US markets' footsteps and opened lower this morning.
Upvote Downvote

 
S&P/ASX 200 set to break its winning streak as US rate hike concerns rise

2018-02-27 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) is unlikely to have a sixth consecutive day in the black with futures pointing to a lower start.
Upvote Downvote

 
S&P/ASX 200 closes on its high for the day, up 0.7%

2018-02-26 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has closed on its high for the day and signficantly, above the 6,000-point level.
Upvote Downvote

 
S&P/ASX 200 gives back some early gains but still holds above 6,000

2018-02-26 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has remained elevated today only giving back 12 points after hitting its high of 6,038.7 earlier this morning.
Upvote Downvote

 
S&P/ASX 200 opens up 0.5% and is holding above 6,000

2018-02-26 proactiveinvestors.com.au
S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO) has opened strongly this morning reaching a high of 6,039 in the first hour of trading.
Upvote Downvote

 
S&P/ASX 200 prepares for final week of reporting season

2018-02-25 proactiveinvestors.com.au
Gold was also largely flat, down US$2.20 to US$1,330 while WTI Crude Oil put on 1.29%, creeping higher to US$63.58 per barrel.
Upvote Downvote

 
Soft start to 2018 as ASX investors sit on their hands

2018-01-02 theage.com.au
The ASX started 2018 on a softer note on Tuesday, as investors held back from adding to the previous year's gains as they waited for clues on market direction.
Upvote Downvote

 
Soft start to 2018 as ASX investors sit on their hands

2018-01-02 smh.com.au
The ASX started 2018 on a softer note on Tuesday, as investors held back from adding to the previous year's gains as they waited for clues on market direction.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...